Stay updated with breaking news from Alex Van Rees. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Analysis Further Highlights the Potential for Zimura to Slow the Progression of Disease and Preserve Foveal Anatomy while Sparing the Foveal Center in Patients with GA - IVERIC bio, Inc. (Nasdaq:
Press release content from Business Wire. The AP news staff was not involved in its creation.
Press release content from Business Wire. The AP news staff was not involved in its creation. IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock July 13, 2021 GMT NEW YORK--(BUSINESS WIRE)--Jul 12, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock at a price to the public of $8.60 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the Company has granted the underwriters an option for a period of 30...
Message : Required fields BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical development candidate, INZ-701, as a potential treatment for ABCC6 Deficiency. The data, presented at the virtual European Calcified Tissue Society Annual Congress (ECTS, May 6-8), are the first to show that an enzyme replacement therapy (ERT) increased plasma pyrophosphate (PPi) levels and reduced...
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting BOSTON, April 08, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced that data from the burden of illness in infantile onset ABCC6 and ENPP1 deficiency study will be presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting taking place April 13-16, 2021. The following poster presentati...